This Week In Cardiology

More on the Million Hearts RCT, ENRICH AF, TAVI vs SAVR, the Partner 3 and Evolut-low-risk trials, and myocardial viability are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Listener Feedback Million Hearts CMS 'Million Hearts' CVD Risk Reduction Model Works https://www.medscape.com/viewarticle/997551 -  RCT JAMA -    https://jamanetwork.com/journals/jama/fullarticle/2810696 AC in ICH - ENRICH AF Oral Anticoagulation in ICH Patients With AF: New Data https://www.medscape.com/viewarticle/997547 -  Lancet Neurology Meta-analysis https://doi.org/10.1016/S1474-4422(23)00315-0 -  ENRICH AF letter https://doi.org/10.1016/S0140-6736(23)02025-1 II.  TAVI vs SAVR Low-Risk TAVR Studies: Divergent Long-Term Results  https://www.medscape.com/viewarticle/997784 -  Partner 3 Main Results -  Partner 3 – Five Year -  Original EVOLUT -LR https://www.nejm.org/doi/10.105